These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 29768183)

  • 1. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
    Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
    He L; Wang X; Liu K; Wu X; Yang X; Song G; Zhang B; Zhong L
    Gene; 2019 Apr; 691():70-76. PubMed ID: 30584903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
    Li W; Jie Z; Li Z; Liu Y; Gan Q; Mao Y; Wang X
    Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
    Shang XB; Yu ZT; Tang P; Zhang XZ
    Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
    Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
    Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
    Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
    Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
    Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
    Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
    Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
    Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
    Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
    Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.